Search Results
Your search for The ASCO matches 21117 pages
Showing 5301 - 5350New IASLC Leadership to Assume Roles at 2021 World Conference on Lung Cancer
Heather Wakelee, MD, will assume the role of President of the International Association for the Study of Lung Cancer (IASLC) at the upcoming IASLC 2021 World Conference on Lung Cancer Denver, Worldwide Virtual Event (WCLC 2021) on September 8 to 14, 2021. Dr. Wakelee has been President-Elect of...
Expert Point of View: Melinda Telli, MD
EA1131 study discussant, Melinda Telli, MD, Associate Professor of Medicine at Stanford University, Director of the Breast Cancer Program at the Stanford Cancer Institute, and Associate Director of the Stanford Women’s Cancer Center, commented: “At this point,1 capecitabine remains preferred as...
Julio Aguirre-Ghiso, PhD, to Lead New Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer Center
Albert Einstein Cancer Center (AECC), Albert Einstein College of Medicine, and Montefiore Health System have announced that cancer biologist Julio Aguirre-Ghiso, PhD, has been named founding Director of the Cancer Dormancy and Tumor Microenvironment Institute (CDTMI), Director of the Gruss-Lipper...
EA1131 Trial: Platinum Not Equal to Capecitabine for Residual Disease in Triple-Negative Breast Cancer
In patients with triple-negative breast cancer who have residual disease after neoadjuvant chemotherapy, adjuvant capecitabine remains the standard of care. In the multicenter randomized noninferiority EA1131 trial, which included primarily basal tumors, noninferiority of adjuvant platinum over...
Expert Point of View: Nicolas Girard, MD, PhD
Invited discussant Nicolas Girard, MD, PhD, of the Curie Institute, Paris, said, “A major challenge in NSCLC is what happens when osimertinib resistance develops.” “A key takeaway point from this study is that the efficacy is driven by resistance mechanism. The overall response rate was 47% in the ...
Amivantamab/Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC
Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive patients with EGFR-mutant non–small cell lung cancer (NSCLC) that had progressed on osimertinib, according to a cohort analysis of the ...
Expert Point of View: Jacqueline C. Barrientos, MD
The invited discussant of the phase I trial of lisaftoclax (APG-2575), Jacqueline C. Barrientos, MD, of Hofstra/Northwell, Great Neck, New York, commented on the positive findings: “The 15 patients with chronic lymphocytic leukemia [CLL] had an objective response rate of 80% and a median time to...
Novel Targeted Agents for the Treatment of Myelofibrosis
“Progress lies not in enhancing what is, but in advancing toward what will be.” –Kahlil Gibran To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting &...
Novel BCL2 Inhibitor Shows Activity in CLL in Phase I Trial
The novel, selective BCL2 inhibitor lisaftoclax (APG-2575) has shown activity in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in a phase I study reported at the 2021 ASCO Annual Meeting.1 Preliminary data suggest that lisaftoclax stands out for its favorable safety...
Expert Point of View: Jacqueline C. Barrientos, MD, MS
Invited discussant Jacqueline C. Barrientos, MD, MS, of Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell in Great Neck, New York, noted that, although both ibrutinib and venetoclax have shown superior results to chemotherapy, each drug is associated with toxicity....
Fixed-Dose, First-Line Ibrutinib/Venetoclax Combination Achieves Durable Remissions in CLL
The combination of fixed-duration, first-line treatment with ibrutinib plus venetoclax achieved complete responses in more than half of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), based on the primary analysis of the fixed-dose cohort of the phase II CAPTIVATE ...
Expert Point of View: Jason J. Luke, MD
Invited discussant of the C-144-01 study,1 Jason J. Luke, MD, Associate Professor of Medicine and Director of the Cancer Immunotherapeutics Center, University of Pittsburgh Hillman Cancer Center, Pittsburgh, noted that lifileucel is “clearly an active regimen in the post–PD-1/CTLA-4 setting and one ...
Early Adopter of Breast Conservation, Surgical Oncologist Augusto Leon, MD, Reflects on Cancer Care in Chile
In this installment of the occasional department on Global Health-Care Equity, Guest Editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Augusto Leon, MD, a surgical oncologist and Head of the Program of Cancer at Pontifical University of Chile, Santiago. Dr. Are is JL & CJ Varner...
Lifileucel After Disease Progression in Metastatic Melanoma: Durable Responses Achieved in Phase II Trial
Despite the fact that we have made significant progress in metastatic melanoma with immune checkpoint inhibitors—now the standard of care—most patients experience disease progression and are left without approved treatments. There is a need for newer treatments with clinical benefit. Lifileucel, an ...
Predicting Global Cancer Trends in 2021
Although we are just halfway through 2021, the outlook for improvements in global cancer trends looks grim. According to new estimates by the International Agency for Research on Cancer’s Global Cancer Observatory, the global cancer burden rose to 19.3 million cases and 10 million deaths in 2020...
ADAPT Trial: ‘Excellent’ Outcomes Reported With Neoadjuvant Dual HER2 Therapy in Breast Cancer
The first overall survival analysis of the WGS-ADAPT HER2+/HR– study, which evaluated neoadjuvant therapy in patients with hormone receptor–negative, HER2-positive disease, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or with the chemotherapy-free regimen of...
Sacituzumab Govitecan-hziy: Welcome Addition to Advanced Urothelial Cancer Treatments, but Time to Figure Out Sequencing and Combinations
The results of Cohort 1 of the phase II trial TROPHY-U-01 (IMMU-132-06; ClinicalTrials.gov identifier NCT03547973), published in the Journal of Clinical Oncology by Tagawa et al and reviewed in this issue of The ASCO Post, led to the recent accelerated U.S. Food and Drug Administration (FDA)...
Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer
The first known clinical trial report of an antibody-drug conjugate was a phase 0/I pharmacodynamic and safety study of a conjugate that targeted carcinoembryonic antigen and delivered a payload of vinca alkaloid in eight patients with ovarian or colorectal cancer.1 This work built on the work of...
New Medical Director Named to Lead Clinical Cancer Research
The University of California (UC) Davis Comprehensive Cancer Center has named Edward Kim, MD, PhD, as Medical Director for the Office of Clinical Research. Dr. Kim is a UC Davis Health oncologist and Associate Professor of Internal Medicine who specializes in treating gastrointestinal...
The Wistar Institute Recruits Noam Auslander, PhD, as Assistant Professor
The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious diseases, recently announced the appointment of Noam Auslander, PhD, as Assistant Professor in the Molecular and Cellular Oncogenesis Program of The Wistar Institute Cancer Center. Dr....
Caryn Lerman, PhD, Elected President of the AACI
Caryn Lerman, PhD, is the new President of the Association of American Cancer Institutes (AACI). Dr. Lerman is Director of the University of Southern California (USC) Norris Comprehensive Cancer Center in Los Angeles and Associate Dean for Cancer Programs and the H. Leslie and Elaine S. Hoffman...
Enfortumab Vedotin-ejfv Granted Regular Approval in Treatment of Locally Advanced or Metastatic Urothelial Cancer
On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and...
Study Finds Response to COVID-19 Vaccination Varies Widely in Patients With Multiple Myeloma
Patients with multiple myeloma had a wide variety of responses to COVID-19 vaccines—in some cases, no detectable response at all—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published by Van Oekelen et al in Cancer Cell. Mount...
Is There a Link Between Use of Antibiotics and Early-Onset Colorectal Cancer?
Study findings presented by Perrott et al at the ESMO World Congress on Gastrointestinal Cancer (Abstract SO-25) showed that the use of antibiotics may be linked to colon tumor formation across all patient age groups, especially in those younger than 50 years. These results raise fresh concerns...
Annual Report to the Nation: Continued Decline in Cancer Death Rate
Overall cancer death rates continue to decline in men and women for all racial and ethnic groups in the United States, according to the latest Annual Report to the Nation on the Status of Cancer. During 2001 to 2018, declines in lung cancer death rates accelerated, and death rates for melanoma...
Using ctDNA to Measure Molecular Residual Disease in Patients With Colorectal Cancer
A team of investigators in Japan used a personalized assay for circulating tumor DNA (ctDNA) levels in plasma to monitor molecular residual disease following surgery in patients with resectable colorectal cancer. Their subgroup analysis found statistically significant associations between ctDNA...
Molecular Imaging May Improve the Staging and Treatment of Pancreatic Ductal Adenocarcinoma
For patients with pancreatic ductal adenocarcinoma, molecular imaging may improve staging and clinical management of the disease, according to research published by Röhrich et al in The Journal of Nuclear Medicine. In a retrospective study of patients with pancreatic ductal adenocarcinomas, the...
Study Recommends Improvements for Cancer Care at Network Sites
New research published in JNCCN—Journal of the National Comprehensive Cancer Network assessed the quality of cancer care delivered through extended sites coordinated by some of the country’s largest cancer centers. The study was developed to implement strategies for disseminating discoveries and...
New Recommendations From WHO and HRP for the Screening and Treatment of Cervical Cancer
The World Health Organization (WHO) and the Human Reproduction Programme (HRP)—the main instrument within the United Nations system for research in human reproduction—have launched a new guideline to help countries make faster progress, more equitably, in the screening and treatment of cervical...
Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates
Research published by Pratt et al in Annals of Surgical Oncology showed an increase in survival rates when treatment options—surgery, chemotherapy, and radiation—are completed within 38 weeks from the time of diagnosis for patients with breast cancer. Optimal Treatment Duration The observational...
Individualized Nutritional Support for Patients With Cancer
Among 506 hospitalized patients with cancer at risk of malnutrition, individualized nutritional support reduced the risk of mortality compared to consumption of standard hospital food. The findings from a preplanned secondary analysis of the prospective, randomized, multicenter EFFORT trial,...
FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma
On July 6, the U.S. Food and Drug Administration (FDA) approved an expanded label for pembrolizumab, an anti–PD-1 agent, as monotherapy for patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation. This approval is based on data from the second...
Study Explores Co-occurring Mutations in HER2 and HER3
Mutations in a gene related to HER2, a gene frequently implicated in breast cancers and a variety of other malignancies, can amplify activity that spurs tumor growth, according to a new study. The findings, published by Hanker et al in Cancer Cell, could explain why many patients with HER2...
Study Suggests Substantial Delays in Diagnosis and Treatment for Cancer During the COVID-19 Pandemic
A new study has found evidence of the adverse effects the COVID-19 pandemic had on cancer detection and surgical treatments. The study, published by Robin Yabroff, PhD, MBA, and colleagues in JNCI: The Journal of the National Cancer Institute, found a 10.2% decline in real-time electronic pathology ...
A Shift in the Treatment of Advanced Melanoma
Answers to questions about first-line treatment of metastatic melanoma are “going to be shifting,” Jason J. Luke, MD, told The ASCO Post, with the change coming on the heels of the phase III RELATIVITY-047 trial reported at the 2021 ASCO Annual Meeting.1 That abstract reported that using two...
Responses to Pembrolizumab and Ipilimumab After Anti–PD-1/L1 Failure in Advanced Melanoma
Despite new and effective treatments for melanoma with checkpoint inhibitors and targeted therapies, patients with metastatic melanoma who progress on frontline treatment generally do very poorly. “We really need to make sure we give these patients access to drugs that we know have some efficacy,”...
FDA Pipeline: Recent Designations in NSCLC, Leukemia, and Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) issued regulatory decisions related to treatments for non–small cell lung cancer (NSCLC), acute leukemia, and mantle cell lymphoma. Breakthrough Therapy Designation for Adagrasib in Advanced NSCLC With KRAS G12C Mutation On June 24, 2021, the...
FDA Approves Alternative to E coli–Derived Asparaginase for Leukemia and Lymphoma
On June 30, 2021, the U.S. Food and Drug Administration (FDA) approved asparaginase Erwinia chrysanthemi (recombinant)-rywn (Rylaze) as a component of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adult and pediatric...
Modified FOLFIRINOX Established as Preferred Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer
In the treatment of borderline resectable pancreatic ductal adenocarcinoma, the Alliance A021501 trial established neoadjuvant treatment with modified FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) as a new benchmark. However, it failed to show the benefit of adding...
Association Between Increased BMI and Endometrial Cancer Risk in Asian Women With Postmenopausal Bleeding
The link between obesity and the risk of endometrial cancer has been well documented. A recent study, however, showed that an even lower body mass index (BMI) than previously thought may be associated with an increased risk in Asian women with postmenopausal bleeding. The findings by Liu et al were ...
Study Examines Impact of COVID-19 on Breast and Cervical Cancer Screening Programs
The total number of cancer screening tests received by women through the Centers for Disease Control and Prevention’s (CDC) National Breast and Cervical Cancer Early Detection Program (Early Detection Program) declined by 87% for breast cancer and 84% for cervical cancer during April 2020 as...
Survey Finds COVID-19 Vaccine Hesitancy Among Many Adolescent and Young Adult Cancer Survivors
Despite recommendations from ASCO and other national organizations that cancer survivors, as well as patients on active treatment, receive the COVID-19 vaccine if they have no contraindications, a survey of adolescent and young adult cancer survivors finds many have vaccine hesitancy. According to...
Study Examines Mechanisms of Resistance in Early-Stage Breast Cancer After Endocrine Plus CDK4/6 Therapy
About 80% of breast cancer cases are hormone receptor–positive, according to the American Cancer Society. Patients with estrogen receptor–positive breast cancer generally are treated using therapy that inhibits both estrogen levels and cell-cycle activity, but about 90% of patients with metastatic...
Immunotherapy May Be Effective for Subset of Patients With Prostate Cancer
In recent years, cancer immunotherapy has been effective in treating patients with immunogenic—or “hot”—tumors with increased levels of inflammation and the presence of immune cells in and around the tumors. Prostate cancer, however, is considered a “cold” tumor, with few immune cells recognizing...
Are Patients With Primary Lung Cancer Detected by Low-Dose CT at Reduced Risk of Brain Metastases?
Patients with primary lung cancer detected using low-dose computed tomography (CT) screening may be at reduced risk for developing brain metastases after diagnosis, according to a study published in the Journal of Thoracic Oncology. The researchers, led by Summer Han, PhD, of Stanford University...
FDA Encourages Inclusion of Patients With Incurable Cancers in Oncology Clinical Trials Regardless of Prior Therapies
On June 24, 2021, Richard Pazdur, MD, Director of the U.S. Food and Drug Administration’s Oncology Center of Excellence and Acting Director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research, made the following statement: “Today, the FDA issued a draft...
News in Genitourinary Cancers From the 2021 ASCO Annual Meeting
This week, we’re focusing on new research in genitourinary cancers presented at the 2021 ASCO Annual Meeting, including renal cell carcinoma and bladder cancer.
Biden Administration Reverses Rule Limiting Access to Equitable Cancer Care for Sexual and Gender Minority Community
On May 10, 2021, the Department of Health and Human Services’ (HHS) Office for Civil Rights announced that its ban on sex discrimination once again includes a ban on discrimination on the basis of sexual orientation and gender identity. The move will reverse a final rule from June 2020 that...
ASCO-ACCC Piloting Project to Test Tools to Diversify Cancer Clinical Trials
In a continuation of their collaboration to increase clinical trial participation among patients from underrepresented racial and ethnic groups, ASCO and the Association of Community Cancer Centers (ACCC) recently announced plans to test a research site assessment tool and implicit bias training...
Watch Now: Discussion on Eligibility Criteria and the Impact on Access to Clinical Trials
On Friday, April 9, 2021, ASCO and Friends of Cancer Research (Friends) co-hosted a live virtual event, which brought together experts from across the health-care sector to discuss the recent release of the new ASCO-Friends recommendations for modernizing eligibility criteria to improve patient...
